VANCOUVER, BC--(Marketwired - July 11, 2016) - On Tuesday, July 12, the Fraser Institute will release a new study comparing Canada's protection of intellectual property (IP) for biologics -- potentially life-saving medicines used to treat cancer and other maladies -- to other countries.

The study, The Biologics Revolution in the Production of Drugs, spotlights how Canada's level of protection -- relative to other countries -- affects investment, innovation and the number of medicines available to Canadians.

A news release with additional information will be issued via Marketwired on July 12 at 5:30 a.m. (Eastern).

Follow the Fraser Institute on Twitter and Facebook

The Fraser Institute is an independent Canadian public policy research and educational organization with offices in Vancouver, Calgary, Toronto, and Montreal and ties to a global network of think-tanks in 87 countries. Its mission is to improve the quality of life for Canadians, their families and future generations by studying, measuring and broadly communicating the effects of government policies, entrepreneurship and choice on their well-being. To protect the Institute's independence, it does not accept grants from governments or contracts for research. Visit www.fraserinstitute.org

Contact Information:

MEDIA CONTACTS:

Kristina Lybecker
Fraser Institute senior fellow

For interviews with Ms. Lybecker, please contact
Aanand Radia
Media Relations Specialist
Fraser Institute
Tel: (416) 363-6575 Ext. 238
E-mail: aanand.radia@fraserinstitute.org